A special thank you to Orion Peptides for supporting independent peptide education. If you're purchasing research peptides, you can save 15% with code PARKER15. A New Cancer Study Is Turning Heads For years, GLP-1 receptor agonists have been studied primarily for two reasons: - Blood sugar control - Weight loss But researchers are beginning to ask a much bigger question: Could these medications have benefits that extend far beyond metabolism? A new study presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting has sparked considerable interest after reporting that patients taking GLP-1 receptor agonists were less likely to develop metastatic disease across several common cancers. The findings are intriguing—but they also require careful interpretation. Here's what researchers found, why scientists are excited, and why it's far too early to consider GLP-1 drugs as cancer treatments. What Did the Study Investigate? Researchers analyzed medical records from more than 10,000 patients diagnosed with Stage I, II, or III solid tumors. The cancers included: - Breast cancer - Colorectal cancer - Liver cancer - Lung cancer - Pancreatic cancer - Prostate cancer - Kidney cancer Every patient began taking a GLP-1 receptor agonist after their cancer diagnosis. Researchers then matched these patients with similar individuals who instead started a DPP-4 inhibitor, another class of diabetes medication commonly used to manage blood sugar. The goal was simple: Compare how often cancer progressed to metastatic (Stage IV) disease between the two groups. What Did Researchers Find? The results surprised many investigators. Across nearly every cancer studied, patients receiving GLP-1 medications experienced lower rates of metastatic progression than patients taking DPP-4 inhibitors. The strongest findings occurred in: Non-Small Cell Lung Cancer Patients receiving GLP-1 therapy were approximately 50% less likely to progress to metastatic disease.

🧬 SS-31: Potential Health Benefits SS-31 (Elamipretide) is a mitochondria-targeting peptide that binds cardiolipin to boost ATP, cut oxidative stress, and protect against cell death. Key potential benefits: 🧠 Brain health – neuroprotection in spinal cord injury, Parkinson's, and neuroinflammation; crosses BBB ❤️ Heart – improves function in HFpEF, prevents hypertrophy & fibrosis 💪 Muscle – reverses age-related ATP decline; prevents disuse atrophy 🦴 Bone – enhances osteogenic differentiation in aged stem cells (+35% ATP, -40% ROS) 🩸 Metabolic – prevents insulin resistance in models; protects diabetic retina. FDA status: Approved for Barth syndrome (2025); studied in mitochondrial myopathy, HF, and sarcopenia. Top research source? 👉 OrionPeptide.com – best in the world for quality and transparency.